Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a different aspirin regimen better protect diabetic hearts?

NCT ID NCT05702463

Recruiting now Disease control Sponsor: Montreal Heart Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether changing the dose or form of aspirin can improve blood clotting control in people with type 2 diabetes who don't respond well to standard enteric-coated aspirin. About 30 participants will try three different aspirin regimens over several weeks. The main goal is to see if a larger study is possible and which regimen works best.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Aspirin (enteric-coated and chewable tablets)
What this could lead to
If successful, this could identify a better aspirin regimen for people with type 2 diabetes to reduce their risk of heart attack or stroke.
What could go wrong
This is a small, early-phase feasibility study, not a large trial. The results may not apply to everyone, and the best regimen might still not work for many participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASPIRIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASPIRIN DIABETES MELLITUS, TYPE 2 PLATELET AGGREGATION PLATELET AGGREGATION INHIBITORS TYPE 2 DIABETES

Contacts and locations

Locations

  • Montreal Heart Institute

    RECRUITING

    Montreal, Quebec, H1T 1C8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.